Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

ASH: Novel menin inhibitors show promise for patients with

Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced

Revumenib Shows Promise in Acute Leukemia - CancerConnect

Clinical Trial Results - Cancer Currents Blog - NCI

PDF) Therapeutic targeting of leukemia stem cells in acute myeloid

Therapeutic implications of menin inhibition in acute leukemias

Cancer Currents: An NCI Cancer Research Blog - NCI

Drug 'cures' 33% of patients with aggressive leukaemia in early

Therapeutic implications of menin inhibition in acute leukemias